A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

Exclusion Criteria

• •Known co-existing bleeding disorders other than congenital hemophilia A or B
• •History of arterial or venous thromboembolism, not associated with an indwelling venous access
• •History of intolerance to SC injection(s).
• •Current participation in immune tolerance induction therapy (ITI)
• •Prior gene therapy
• •Current or prior participation in a fitusiran trial
• •Current or prior participation in a gene therapy trial
• •Received an investigational drug or device within 30 days prior to the screening visit or within 5 half-lives of the investigational drug (or device) prior to the screening visit, whichever is longer
• •Presence of clinically significant liver disease AT activity \<60% at Screening
• •Co-existing thrombophilic disorder
• •Hepatitis C virus antibody positive, except participants who have negative Hepatitis C viral load and no evidence of cirrhosis
• •Presence of acute hepatitis, ie, hepatitis A, hepatitis E.
• •Presence of acute or chronic hepatitis B infection
• •Known to be HIV positive with CD4 count \<200 cells/μL.
• •Reduced renal function The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.